CardioExchange Archive

September 15th, 2014

New Observations on Saxagliptin

Benjamin Scirica, MD MPH

Benjamin Scirica discusses his study group’s new analysis of data from the SAVOR-TIMI 53 randomized, placebo-controlled trial of saxagliptin in patients with type 2 diabetes.

---

February 11th, 2014

FDA Investigating Heart Failure Risk Linked to Saxagliptin

Larry Husten, PHD

The FDA said today that it is conducting an investigation of a possible increased risk for heart failure associated with the diabetes drug saxagliptin. Saxagliptin, a dipeptidyl peptidase 4 inhibitor, is marketed by AstraZeneca as Onglyza and Kombiglyze XR. (AstraZeneca recently completed the purchase of all rights to the drug from its manufacturer, Bristol Myers-Squibb.) The investigation stems […]

---

October 7th, 2013

Selections from Richard Lehman’s Literature Review: October 7th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include several papers on the CV safety of diabetes drugs, a follow-up report from the WHI on hormone therapy, clopidogrel and smoking, and more.

---

September 2nd, 2013

Cardiovascular Outcome Studies in Diabetes Drugs Finally Arrive

Larry Husten, PHD

Large trials of two diabetes drugs show that they appear to be safe, but do not improve CV outcomes.

---

June 19th, 2013

Top-Line Results: No Cardiovascular Benefits Found For Saxagliptin

Larry Husten, PHD

Top-line results of a large phase 4 study with saxagliptin (Onglyza, Bristol-Myers Squibb and AstraZeneca) demonstrate that the drug is safe but has no cardiovascular benefits. AstraZeneca and Bristol-Myers Squibb today announced the top-line results for the SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza®. The full results are scheduled to presented at the annual meeting of the European Society of Cardiology in Amsterdam on September 2 […]

---